Rare lephants
Screener

FIREFLY NEUROSCIENCE, INC.

AIFF ·Technology, Software - Application, United States
Analysis › Moat Score

Moat Score — Firefly Neuroscience, Inc.

Total Moat Score 7 / 30
Moat Factor Score Analysis
Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. 3 / 5 23 issued U.S. patents, FDA 510(k) clearance, CE marking, and a proprietary database of 191,000+ EEG/ERP records give real, if unproven-at-scale, IP protection.
Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. 0 / 5 As a 17-employee, cash-burning pre-commercial company, Firefly has no cost advantage over larger medtech or digital-health competitors.
Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. 1 / 5 Subscription/overage pricing exists but is unproven; minimal current revenue suggests limited ability to command premium pricing yet.
Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. 1 / 5 The reference database improves with more clinical data collected, giving a mild data network effect, but scale (85 sites) is still small.
Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. 2 / 5 Once a clinic installs the Evoke hardware and trains staff on the analytics workflow, switching to another EEG diagnostic system involves real retraining and workflow disruption.
Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. 0 / 5 The neurodiagnostic AI space is attracting many well-capitalized digital-health entrants, and Firefly's niche is not protected by limited market size.